title: The use of intravenous antibiotics at the onset of neutropenia in patients receiving outpatient-based hematopoietic stem cell transplants.
abstract: Empirical antibiotics at the onset of febrile neutropenia are one of several strategies for management of bacterial infections in patients undergoing Hematopoietic Stem Cell Transplant (HSCT) (empiric strategy). Our HSCT program aims to perform HSCT in an outpatient setting, where an empiric antibiotic strategy was employed. HSCT recipients began receiving intravenous antibiotics at the onset of neutropenia in the absence of fever as part of our institutional policy from 01 Jan 2009; intravenous Prophylactic strategy. A prospective study was conducted to compare two consecutive cohorts [Year 2008 (Empiric strategy) vs. Year 2009 (Prophylactic strategy)] of patients receiving HSCT. There were 238 HSCTs performed between 01 Jan 2008 and 31 Dec 2009 with 127 and 111 in the earlier and later cohorts respectively. Infection-related mortality pre- engraftment was similar with a prophylactic compared to an empiric strategy (3.6% vs. 7.1%; p = 0.24), but reduced among recipients of autologous HSCT (0% vs. 6.8%; p = 0.03). Microbiologically documented, blood stream infections and clinically documented infections pre-engraftment were reduced in those receiving a prophylactic compared to an empiric strategy, (11.7% vs. 28.3%; p = 0.001), (9.9% vs. 24.4%; p = 0.003) and (18.2% vs. 33.9% p = 0.007) respectively. The prophylactic use of intravenous once-daily ceftriaxone in patients receiving outpatient based HSCT is safe and may be particularly effective in patients receiving autologous HSCT. Further studies are warranted to study the impact of this Prophylactic strategy in an outpatient based HSCT program.
authors.affiliation: The Ottawa Hospital Blood and Marrow Programme, The Ottawa Hospital, Ottawa, Ontario, Canada.
authors.forename: Aziz
authors.initials: A
authors.lastname: Hamadah
authors.forename: Yoko
authors.initials: Y
authors.lastname: Schreiber
authors.forename: Baldwin
authors.initials: B
authors.lastname: Toye
authors.forename: Sheryl
authors.initials: S
authors.lastname: McDiarmid
authors.forename: Lothar
authors.initials: L
authors.lastname: Huebsch
authors.forename: Christopher
authors.initials: C
authors.lastname: Bredeson
authors.forename: Jason
authors.initials: J
authors.lastname: Tay
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000517:prevention & control*; D002443:Ceftriaxone / Q000008:administration & dosage*; D005260:Female; D005334:Fever / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D010045:Outpatients; D011446:Prospective Studies; D015996:Survival Rate; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D000900:Anti-Bacterial Agents; D002443:Ceftriaxone